Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONCY Oncolytics Biotech Inc

Closed 07-02 16:00:00 EDT

0.9900

-0.0052

-0.52%

盘后0.9900

+0.00000.00%

18:01 EDT

High1.01	Low0.9900	Vol181.29K
Open0.9900	D1 Closing0.9952	Amplitude2.01%
Mkt Cap75.55M	Tradable Cap72.35M	Total Shares76.31M
T/O180.51K	T/O Rate0.25%	Tradable Shares73.08M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ONCY","market":"US","secType":"STK","nameCN":"Oncolytics Biotech Inc","latestPrice":0.99,"timestamp":1719950400000,"preClose":0.9952,"halted":0,"volume":181294,"hourTrading":{"tag":"盘后","latestPrice":0.99,"preClose":0.99,"latestTime":"18:01 EDT","volume":651,"amount":646.001572,"timestamp":1719957683153},"delay":0,"floatShares":73079646,"shares":76310671,"eps":-0.294033,"marketStatus":"Closed","change":-0.0052,"latestTime":"07-02 16:00:00 EDT","open":0.99,"high":1.01,"low":0.99,"amount":180505.05564844,"amplitude":0.020096,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.294033,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1719993600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1002254400000,"exchange":"NASDAQ","adjPreClose":0.9952,"preHourTrading":{"tag":"盘前","latestPrice":1.03,"preClose":0.9952,"latestTime":"08:28 EDT","volume":45,"amount":46.35,"timestamp":1719923305085},"postHourTrading":{"tag":"盘后","latestPrice":0.99,"preClose":0.99,"latestTime":"18:01 EDT","volume":651,"amount":646.001572,"timestamp":1719957683153},"volumeRatio":1.023283},"requestUrl":"/m/hq/s/ONCY/tweets","defaultTab":"tweets","newsList":[{"id":"2446381535","title":"Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2446381535","media":"CNW Group","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446381535?lang=en_us&edition=fundamental","pubTime":"2024-06-27 19:00","pubTimestamp":1719486000,"startTime":"0","endTime":"0","summary":"Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer. On track to report overall survival results from the randomized HR+/HER2- metastatic breast cancer BRACELET-1 trial in H2 2024. SAN DIEGO and CALGARY, AB, June 27, 2024 /CNW/ -- Oncolytics BiotechInc.  , a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that the Company received productive feedback from its Type C meeting with the U.S. Food and Drug Administration , supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer . The FDA supports progression-free survival as the primary endpoint of the study, with overall survival as a key secondary endpoint. The Company's proposed study will enroll patients who have failed hormonal therapy and have received no more than one line of antibody-drug conjugate  therapy.About Oncolytics Biotech Inc.Oncolytics is a clin","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8xZt9E4oiRJDQXgoODi..Q--~B/aD0xNzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/6f3fee9112cd498f5706afb24313777e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8xZt9E4oiRJDQXgoODi..Q--~B/aD0xNzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/6f3fee9112cd498f5706afb24313777e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-announces-productive-fda-110000136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4231","ADC","ONCY","BK4080"],"gpt_icon":0},{"id":"2445730160","title":"Oncolytics Biotech CEO Matt Coffey to Take Medical Leave of Absence","url":"https://stock-news.laohu8.com/highlight/detail?id=2445730160","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2445730160?lang=en_us&edition=fundamental","pubTime":"2024-06-24 20:11","pubTimestamp":1719231065,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech  said Monday that Chief Executive Officer Matt Coffey will take a medical leave of absence, effective immediately.Wayne Pisano, chair of Oncolytics' board of directors since 2013, will serve as interim CEO during his absence.Price: 0.9900, Change: -0.02, Percent Change: -1.98","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2445022145","title":"Press Release: Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence","url":"https://stock-news.laohu8.com/highlight/detail?id=2445022145","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2445022145?lang=en_us&edition=fundamental","pubTime":"2024-06-24 19:00","pubTimestamp":1719226800,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence. Wayne Pisano, Chair of Oncolytics' Board of Directors, to serve as interim CEO. SAN DIEGO and CALGARY, AB, June 24, 2024 /CNW/ -- Oncolytics Biotech Inc.  , a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that Matt Coffey, PhD, President and Chief Executive Officer of Oncolytics will take a medical leave of absence, effective immediately. Wayne Pisano, Chair of Oncolytics' Board of Directors, will serve as the interim CEO during Dr. Coffey's absence.Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metasta","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4022","BK4232","ONCY","BK4139"],"gpt_icon":0},{"id":"2444290477","title":"Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2444290477","media":"PR Newswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444290477?lang=en_us&edition=fundamental","pubTime":"2024-06-20 19:26","pubTimestamp":1718882760,"startTime":"0","endTime":"0","summary":"Demonstrating pelareorep's synergy with modified FOLFIRINOX +/- atezolizumab in pancreatic cancer could expand the number of patients it may benefit. Funding for the study comes from the US$5 million Therapeutic Accelerator Award from PanCAN. SAN DIEGO, and CALGARY, AB, June 20, 2024 /PRNewswire/ -- Oncolytics BiotechInc.  , a leading clinical-stage company specializing in immunotherapeutics for oncology, announced the dosing of the first patient in the new GOBLET study cohort evaluating pelareorep and modified FOLFIRINOX  with or without atezolizumab  in newly diagnosed metastatic pancreatic ductal adenocarcinoma  patients. The co-primary endpoints of the cohort are objective response rate  and safety. It is supported by the US$5M Pancreatic Cancer Action Network  Therapeutic Accelerator Award, an innovative program established to accelerate the development of new treatments for pancreatic cancer patients. It will be conducted in collaboration with AIO-Studien-gGmbH , a clinical trial","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_DoiqDPx_k0_nZ0xF335Kw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/aa5c420d85d2a4222522824133cb3d72","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_DoiqDPx_k0_nZ0xF335Kw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/aa5c420d85d2a4222522824133cb3d72"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/oncolytics-biotech-doses-first-patient-112600124.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-doses-first-patient-112600124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ONCY","AIO"],"gpt_icon":0},{"id":"2437039505","title":"Oncolytics Biotech Says ASCO Abstracts Highlight Pelareorep's Treatment Potential in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2437039505","media":"MT Newswires","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2437039505?lang=en_us&edition=fundamental","pubTime":"2024-05-24 19:34","pubTimestamp":1716550470,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech  on Friday said it presented two abstracts ahead of the 2024 American Society of Clinical Oncology  Annual Meeting, which runs from May 31 - June 4, 2024, in Chicago.The abstracts show the company's lead candidate pelareorep's role in cancer treatment. One is a trial-in-progress abstract discussing cohort 5 of the GOBLET study, which will evaluate the combination of pelareorep and modified Folfirinox  with and without atezolizumab in newly diagnosed metastatic pancreatic ductal adenocarcinoma  patients.The second describes pelareorep's ability to induce the expansion of tumor-infiltrating lymphocytes  across multiple cancers and the correlation between TIL expansion and tumor response.\"The two abstracts that we are sharing at ASCO this year are in synch with our mission of advancing pelareorep towards registrational trials,\" said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics.Should pelareorep and mFolfirinox produce a similarly positive outcome","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-says-asco-abstracts-113430356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ONCY"],"gpt_icon":0},{"id":"2437038605","title":"Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action","url":"https://stock-news.laohu8.com/highlight/detail?id=2437038605","media":"CNW Group","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2437038605?lang=en_us&edition=fundamental","pubTime":"2024-05-24 19:00","pubTimestamp":1716548400,"startTime":"0","endTime":"0","summary":"Trial-in-progress abstract highlights new cohort that could expand the company's pancreatic cancer program. Pelareorep's ability to expand TILs highlights its immunotherapeutic mechanism of action and potential as a backbone immunotherapy for multiple indications. Thomas Heineman, MD, PhD, Chief Medical Officer of Oncolytics stated, \"Pelareorep stimulates a proinflammatory response that primes tumors for immunologic killing and also activates both innate and adaptive immune responses. Our second ASCO abstract provides additional support for pelareorep's immunotherapeutic mechanism of action by describing its ability to stimulate the expansion of pre-existing and new TIL clones in the blood, which correlate with treatment response. These results build upon previously reported data from the AWARE-1 study in breast cancer to expand our understanding ofpelareorep's immune-based mechanism of action, and it supports further investigation of TIL expansion as a potential biomarker of clinical ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8xZt9E4oiRJDQXgoODi..Q--~B/aD0xNzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/6f3fee9112cd498f5706afb24313777e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8xZt9E4oiRJDQXgoODi..Q--~B/aD0xNzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/6f3fee9112cd498f5706afb24313777e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-asco-abstracts-highlight-110000439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4157","LINK","BK4139","ONCY","AIO"],"gpt_icon":0},{"id":"2435755586","title":"Press Release: Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2435755586","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435755586?lang=en_us&edition=fundamental","pubTime":"2024-05-16 19:00","pubTimestamp":1715857200,"startTime":"0","endTime":"0","summary":"SAN DIEGO and CALGARY, AB, May 16, 2024 /CNW/ -- Oncolytics Biotech Inc.  , a leading clinical-stage company specializing in immunotherapy for oncology, today announced the voting results from its Annual General Meeting  of Shareholders held on Wednesday, May 15, 2024. A total of 41.34% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.On a vote by ballot, the eight nominees proposed by the Corporation were elected as Directors of Oncolytics to serve until the Corporation's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows:. Deborah M. Brown     8,154,250  74.81 %  2,746,241  25.19 %. Angela Holtham       8,451,056  77.53 %  2,449,435  22.47 %. Jonathan Rigby       8,372,251  76.81 %  2,528,240  23.19 %. Bernd R. Seizinger   8,883,087  81.49 %  2,017,404  18.51 %. Pelareorep has demonstra","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","ONCY","AGM","BK4195","BK4232","BK4139","R","BK4229","AGM.AU"],"gpt_icon":0},{"id":"2435463683","title":"Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2435463683","media":"CNW Group","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435463683?lang=en_us&edition=fundamental","pubTime":"2024-05-15 19:00","pubTimestamp":1715770800,"startTime":"0","endTime":"0","summary":"Anticipated evaluation to include combination therapy featuring treatment regimen of checkpoint inhibition and chemotherapy utilized in cohort 1 of the GOBLET study. GCAR is launching a new master protocol for pancreatic cancer with the intent to create a registration-enabling pathway for investigational therapies. Innovative adaptive design could accelerate registrational study timeline and provide substantial cost savings compared to traditional trial designs. Meredith Buxton, PhD, MPH, Chief Executive Officer and President of GCAR, commented, \"Our unwavering mission at GCAR is to accelerate the development of treatments for patients with deadly diseases such as pancreatic cancer. We believe that adaptive platform trials have the potential to achieve that mission and to be game-changing for patients. We are enthusiastic about collaborating with Oncolytics on our planned pancreatic cancer initiative, which was announced earlier this year, and we look forward to working with Oncolytics","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cg_T5Jo0SUXXOvycUE1WCQ--~B/aD0xNzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/caf9efe53f239ce497937f5fab3fe90d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cg_T5Jo0SUXXOvycUE1WCQ--~B/aD0xNzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/caf9efe53f239ce497937f5fab3fe90d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-announces-preliminary-collaboration-110000075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ONCY"],"gpt_icon":0},{"id":"2435323276","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oncolytics Biotech (ONCY), Aveanna Healthcare Holdings (AVAH) and Sanofi (OtherSNYNF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435323276","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435323276?lang=en_us&edition=fundamental","pubTime":"2024-05-13 18:40","pubTimestamp":1715596826,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Oncolytics Biotech (ONCY – Research Report), Aveanna Healthcare H...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-oncolytics-biotech-oncy-aveanna-healthcare-holdings-avah-and-sanofi-othersnynf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-oncolytics-biotech-oncy-aveanna-healthcare-holdings-avah-and-sanofi-othersnynf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNYNF","BK4196","AVAH","BK4139","BK4007","ONCY","BK4539"],"gpt_icon":0},{"id":"2434876622","title":"Analysts Are Bullish on These Healthcare Stocks: Oncolytics Biotech (ONCY), Lineage Therap (LCTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2434876622","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434876622?lang=en_us&edition=fundamental","pubTime":"2024-05-12 00:00","pubTimestamp":1715443231,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oncolytics Biotech (ONCY – Research Report) and Line...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-oncolytics-biotech-oncy-lineage-therap-lctx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-oncolytics-biotech-oncy-lineage-therap-lctx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","LCTX","BK4139","ONCY","BK4137"],"gpt_icon":0},{"id":"2434891991","title":"Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2024 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2434891991","media":"Insider Monkey","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434891991?lang=en_us&edition=fundamental","pubTime":"2024-05-11 04:35","pubTimestamp":1715373307,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc.  Q1 2024 Earnings Call Transcript May 9, 2024 Oncolytics Biotech Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (. In any forward looking statements, which are politically expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis. But there can be no assurance that the statement or expectation or belief will be achieved. These factors include results of current or pending clinical trials, risks associated intellectual property protection, financial projections, actions by regulatory agencies, and those other factors detailed in the company's filings with SEDAR and the SEC. I'm going to undertake undertake any obligation to update these forward-looking statements, except as required by applicable laws. I'm joined by several members of the Oncolytics management team to review our first quarter 2024 results and corporat","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_FbrCaz8LS5fa8LCm7g0qw--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/36ee815c30e063a02613bdfb330dbfe2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_FbrCaz8LS5fa8LCm7g0qw--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/36ee815c30e063a02613bdfb330dbfe2"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-inc-nasdaq-oncy-203507484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","ONCWF","NDAQ","ONCY"],"gpt_icon":0},{"id":"2434040463","title":"Oncolytics Biotech Q1 EPS $(0.07) Beats $(0.08) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2434040463","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434040463?lang=en_us&edition=fundamental","pubTime":"2024-05-10 04:35","pubTimestamp":1715286905,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech (NASDAQ:ONCY) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is unchanged from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38745481/oncolytics-biotech-q1-eps-0-07-beats-0-08-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY"],"gpt_icon":0},{"id":"2434040967","title":"Oncolytics Biotech GAAP EPS of -$0.09 misses by $0.01","url":"https://stock-news.laohu8.com/highlight/detail?id=2434040967","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434040967?lang=en_us&edition=fundamental","pubTime":"2024-05-10 04:25","pubTimestamp":1715286346,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech press release (NASDAQ:ONCY): Q1 GAAP EPS of -$0.09  misses by $0.01. As of March 31, 2024, the Company reported $29.6 million in cash and cash equivalents, with a projected cash run","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104096-oncolytics-biotech-gaap-eps-of-0_09-misses-0_01","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2434989047","title":"Press Release: Oncolytics Biotech(R) Reports First Quarter 2024 Financial Results and Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2434989047","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434989047?lang=en_us&edition=fundamental","pubTime":"2024-05-10 04:01","pubTimestamp":1715284860,"startTime":"0","endTime":"0","summary":"Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- metastatic breast cancer. Overall survival data from BRACELET-1 breast cancer study expected in H2 2024. Cash position of $29.6 million provides runway through critical milestones into 2025. Dr. Coffey continued, \"Looking ahead, Oncolytics is focused on advancing pelareorep towards registration-enabling studies in breast and pancreatic cancer that will lead to the broad adoption of pelareorep as a treatment for cancer. We are optimistic about the potential for pelareorep to improve the care of cancer patients and look forward to updating investors with our progress on these important milestones.\". FDA Type C meeting granted to discuss plans for breast cancer. Oncolytics has been granted a meeting with the FDA to discuss the Company's planned registration-enabling study for pelareorep in HR+/HER2- metastatic breast cancer. Aligning with the FDA on the design and objectives of a registr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4022","BK4139","R","ONCY"],"gpt_icon":0},{"id":"2434210042","title":"Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2434210042","media":"PR Newswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434210042?lang=en_us&edition=fundamental","pubTime":"2024-05-10 04:01","pubTimestamp":1715284860,"startTime":"0","endTime":"0","summary":"Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- metastatic breast cancer. Overall survival data from BRACELET-1 breast cancer study expected in H2 2024. Cash position of $29.6 million provides runway through critical milestones into 2025. Dr. Coffey continued, \"Looking ahead, Oncolytics is focused on advancing pelareorep towards registration-enabling studies in breast and pancreatic cancer that will lead to the broad adoption of pelareorep as a treatment for cancer. We are optimistic about the potential for pelareorep to improve the care of cancer patients and look forward to updating investors with our progress on these important milestones.\". FDA Type C meeting granted to discuss plans for breast cancer. Oncolytics has been granted a meeting with the FDA to discuss the Company's planned registration-enabling study for pelareorep in HR+/HER2- metastatic breast cancer. Aligning with the FDA on the design and objectives of a registr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/i5RMwN3trQMNIFldeYIXCg--~B/aD0xNzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/caf9efe53f239ce497937f5fab3fe90d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/i5RMwN3trQMNIFldeYIXCg--~B/aD0xNzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/caf9efe53f239ce497937f5fab3fe90d"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/oncolytics-biotech-reports-first-quarter-200100610.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-reports-first-quarter-200100610.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ONCY"],"gpt_icon":0},{"id":"2434311093","title":"Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2434311093","media":"CNW Group","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434311093?lang=en_us&edition=fundamental","pubTime":"2024-05-09 19:00","pubTimestamp":1715252400,"startTime":"0","endTime":"0","summary":"US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study. SAN DIEGO and CALGARY, AB, May 9, 2024 /CNW/ --Oncolytics BiotechInc.  , a leading clinical-stage company specializing in immunotherapy for oncology, will commence enrollment into a new GOBLET study pancreatic cancer cohort following both German regulatory and ethics approvals. This cohort will evaluate pelareorep in combination with modified FOLFIRINOX  with or without the PD-L1 immune checkpoint inhibitor atezolizumab  in newly diagnosed patients with pancreatic ductal adenocarcinoma . It is supported by a US$5M Therapeutic Accelerator Award from the Pancreatic Cancer Action Network , an innovative program established to accelerate the development of new treatments for pancreatic cancer. The chemotherapy regimens of mFOLFIRINOX or gemcitabine + nab-paclitaxel are the two most common standards of care for pancreatic cancer.1 Oncolytics has already reported data with the combination of gemcit","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cg_T5Jo0SUXXOvycUE1WCQ--~B/aD0xNzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/caf9efe53f239ce497937f5fab3fe90d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cg_T5Jo0SUXXOvycUE1WCQ--~B/aD0xNzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/caf9efe53f239ce497937f5fab3fe90d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-receives-regulatory-clearance-110000892.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ONCY","LU1023057109.AUD","BK4552","AIO","BK4139","BK4563","BK4526","BK4531","BK4509","BK4535","BK4571","BK4023","LU1169589451.USD","LU0359202008.SGD","LU1169590202.USD","PD","TME","BK4565","BK4548","BK4108","LU0359201612.USD"],"gpt_icon":0},{"id":"2433742596","title":"Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2433742596","media":"PR Newswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2433742596?lang=en_us&edition=fundamental","pubTime":"2024-05-08 19:00","pubTimestamp":1715166000,"startTime":"0","endTime":"0","summary":"SAN DIEGO and CALGARY, AB, May 8, 2024 /PRNewswire/ -- Oncolytics BiotechInc.  , a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference, which is taking place May 14-15, 2024 at the InterContinental New York Barclay in New York, NY. Additional details on the fireside chat can be found below.Date: Wednesday, May 15, 2024Time: 10:30 a.m. ETLocation: InterContinental New York Barclay Grand Ballroom I, 2nd FloorWebcast Link: Available by clicking here. Company management will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, contact your RBC representative or email jpatton@oncolytics.ca.A live webcast of the Company's presentation will also be available on the Investor Relations page of Oncolytics' website  and will be archived until August 13, 2024.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/V4HsdfDOffpXrk.cqSWj5Q--~B/aD0xNzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/6f3fee9112cd498f5706afb24313777e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/V4HsdfDOffpXrk.cqSWj5Q--~B/aD0xNzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/6f3fee9112cd498f5706afb24313777e"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/oncolytics-biotech-participate-fireside-chat-110000200.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-participate-fireside-chat-110000200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ONCY","BK4157","HCSG","BK4137","BK4139","BK4207","LINK"],"gpt_icon":0},{"id":"2431190312","title":"Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2431190312","media":"PR Newswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431190312?lang=en_us&edition=fundamental","pubTime":"2024-04-30 19:00","pubTimestamp":1714474800,"startTime":"0","endTime":"0","summary":"Conference call and webcast to take place on Thursday, May 9, 2024, at 4:30 p.m. ET. SAN DIEGO and CALGARY, AB, April 30, 2024 /PRNewswire/ --Oncolytics BiotechInc.  , a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter 2024.A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clickinghere, and will be archived for three months. A dial-in replay will be available for one week and can be accessed by dialing  660-6345  or  819-1450  and using replay code: 77797#.Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/V4HsdfDOffpXrk.cqSWj5Q--~B/aD0xNzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/6f3fee9112cd498f5706afb24313777e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/V4HsdfDOffpXrk.cqSWj5Q--~B/aD0xNzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/6f3fee9112cd498f5706afb24313777e"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/oncolytics-biotech-host-conference-call-110000713.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-host-conference-call-110000713.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4181","ONCY","BK4588","HST","BK4585","BK4218"],"gpt_icon":0},{"id":"2430681405","title":"Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2430681405","media":"PR Newswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2430681405?lang=en_us&edition=fundamental","pubTime":"2024-04-25 19:00","pubTimestamp":1714042800,"startTime":"0","endTime":"0","summary":"SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics BiotechInc.  , a leading clinical-stage company specializing in immunotherapy for oncology, today announced the acceptance of two abstracts at the 2024 American Society of Clinical Oncology  Annual Meeting, which is taking place from May 31 – June 4, 2024, in Chicago, Illinois. Details on the abstracts and poster presentation are shown below.Title: Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma.Abstracts will be published on the ASCO Annual Meeting website at 5:00 p.m. ET on May 23, 2024.Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It act","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8Hn0kGeIbmOFkCVLjaAfEQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/3f02ea8fa7c51ecc766276724e17f4cd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8Hn0kGeIbmOFkCVLjaAfEQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/3f02ea8fa7c51ecc766276724e17f4cd"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/oncolytics-biotech-announces-upcoming-presentations-110000211.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-announces-upcoming-presentations-110000211.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4117","AFG","BK4107","BK4139","ONCY"],"gpt_icon":0},{"id":"2426263362","title":"Oncolytics seeking FDA meeting to discuss registration-enabling study","url":"https://stock-news.laohu8.com/highlight/detail?id=2426263362","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2426263362?lang=en_us&edition=fundamental","pubTime":"2024-04-11 22:00","pubTimestamp":1712844056,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech  said it has requested a Q2 meeting with the FDA to discuss the design and objectives of a planned registration-enabling study for its breast cancer drug candidate pelareoprep. The biotech company is testing the product for the treatment of HR+/HER2- metastatic breast cancer. Overall survival results from a Phase 2 study called BRACELET-1 are expected in the second half of the year, according to the company.  More on Oncolytics Biotech  Oncolytics Biotech, Inc.  Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Oncolytics Biotech Historical earnings data for Oncolytics Biotech Financial information for Oncolytics Biotech","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1387472103/image_1387472103.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1387472103/image_1387472103.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4088943-oncolytics-seeking-fda-meeting-to-discuss-registration-enabling-study","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["ONCY","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oncolyticsbiotech.com","stockEarnings":[{"period":"1week","weight":-0.0147},{"period":"1month","weight":-0.0699},{"period":"3month","weight":-0.0699},{"period":"6month","weight":-0.2489},{"period":"1year","weight":-0.6172},{"period":"ytd","weight":-0.2628}],"compareEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":0.0341},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1633},{"period":"1year","weight":0.2302},{"period":"ytd","weight":0.1473}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.015992},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.043175},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.095393},{"month":4,"riseRate":0.666667,"avgChangeRate":0.020376},{"month":5,"riseRate":0.333333,"avgChangeRate":0.056551},{"month":6,"riseRate":0.166667,"avgChangeRate":0.01008},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.041087},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.113494},{"month":9,"riseRate":0,"avgChangeRate":-0.07587},{"month":10,"riseRate":0.5,"avgChangeRate":0.164298},{"month":11,"riseRate":0.333333,"avgChangeRate":0.085795},{"month":12,"riseRate":0.166667,"avgChangeRate":0.384182}],"exchange":"NASDAQ","name":"Oncolytics Biotech Inc","nameEN":"Oncolytics Biotech Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oncolytics Biotech Inc,ONCY,Oncolytics Biotech Inc股票,Oncolytics Biotech Inc股票老虎,Oncolytics Biotech Inc股票老虎国际,Oncolytics Biotech Inc行情,Oncolytics Biotech Inc股票行情,Oncolytics Biotech Inc股价,Oncolytics Biotech Inc股市,Oncolytics Biotech Inc股票价格,Oncolytics Biotech Inc股票交易,Oncolytics Biotech Inc股票购买,Oncolytics Biotech Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction